Ulster University Logo

Ulster Institutional Repository

Daily administration of the GIP-R antagonist (Pro(3))GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro(3))GIP

Biomedical Sciences Research Institute Computer Science Research Institute Environmental Sciences Research Institute Nanotechnology & Advanced Materials Research Institute

McClean, Paula, Gault, Victor, Irwin, Nigel, McCluskey, Janie and Flatt, Peter (2008) Daily administration of the GIP-R antagonist (Pro(3))GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro(3))GIP. DIABETES OBESITY AND METABOLISM, 10 (4). pp. 336-342. [Journal article]

Full text not available from this repository.

DOI: 10.1111/j.1463-1326.2007.00712.x

Abstract

Aim: Glucose-dependent insulinotropic polypeptide-receptor (GIP-R) antagonism using (Pro(3))GIP improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure and function in a commonly used model of obesity-diabetes, namely ob/ob mice. The effect of GIP-R antagonism in a streptozotocin (STZ)-induced model of insulin deficiency has not been evaluated. The present study has investigated the effects of daily administration of (Pro(3))GIP to STZ-treated mice. Methods: Swiss TO mice received once-daily injection of (Pro(3))GIP (25 nmol/kg body weight) or saline 4 days prior to and 16 days after injection of STZ, and effects on metabolic parameters and islet architecture were assessed. Results: (Pro(3))GIP treatment had no significant effect on hyperphagia or body weight loss. However, hyperglycaemia and glycated haemoglobin were worsened, glucose tolerance further decreased and insulin sensitivity was impaired by (Pro(3))GIP. These effects were observed on an STZ-induced background characterized by severe reductions of circulating insulin, beta-cell mass and pancreatic insulin stores. Conclusions: These data indicate that the beneficial actions of the GIP-R antagonist, (Pro(3))GIP, in obesity-diabetes appear to be largely mediated through insulin-dependent mechanisms that merit further investigation.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Faculty of Life and Health Sciences > School of Pharmacy and Pharmaceutical Science
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
Biomedical Sciences Research Institute > Stratified Medicine
ID Code:2918
Deposited By:Professor Peter Flatt
Deposited On:17 Dec 2009 10:09
Last Modified:15 Oct 2013 16:38

Repository Staff Only: item control page